Document is current

Article History

Received: 17 April 2021

Accepted: 3 September 2021

First Online: 4 October 2021

Declarations

:

: Prior to any study activity, the proposed protocol and CRFs were reviewed and approved by a central ethics committee (Institutional Review Board Services, now part of Advarra), and local ethics review boards (Halton Healthcare Research Ethics Committee, Nova Scotia Health Authority Research Ethics Board [File number 1021786]) as required for individual sites. Where applicable, patient consent for review of their charts was sought.

: Not applicable.

: JvS has received compensation for serving as a consultant and speaker for Janssen, Purdue Pharma, and Takeda Canada Inc. JvS has also received educational grants from Janssen, Purdue Pharma, and Takeda Canada Inc., and research grants from Emalex, Janssen, Nuvelution, Purdue Pharma, Takeda Canada Inc., Biohaven and Teva. JvS has also participated in advisory boards and speaker bureaus for Janssen, Purdue Pharma, and Takeda Canada Inc. JvS owns stocks in Johnson & Johnson. SKG is an employee of Takeda Canada Inc. SKG owns stock/stock options in Takeda. CJR was an employee of Shire Pharma Canada ULC (now Takeda Canada Inc.) at the time of the study. CJR is currently an employee of Medison Canada. KH has received research grants and speaking honoraria from Takeda Canada Inc., and has acted on advisory boards and speaker bureaus for Sunovion, Janssen, Purdue, and Takeda Canada Inc.